Aurelio Maggio: Is It Time to Align Thalassemia Biology with Regulatory Science?
Aurelio Maggio, President of Foundation Franco and Piera Cutino, shared on LinkedIn:
”A Century After Cooley: Is It Time to Align Thalassemia Biology with Regulatory Science?
March 18–21, 2027 | Palermo, Italy
International GRADE-Based Consensus Conference
GARDEN Network – Global Hematological Rare Diseases Alliance
In 1925, Thomas Benton Cooley described what he called ‘Erythroblastic Anemia’, recognizing a profound disturbance in erythroid development.
More than a century later, thalassemia remains primarily classified as a globin gene disorder.
That molecular basis remains central.
However, translational evidence is expanding the framework.
Dysregulated hematopoietic stem cell (HSC) biology.
Persistent stress erythropoiesis. Metabolic hyperactivation. Epigenetic modulation.
These mechanisms appear to influence phenotypic heterogeneity, treatment responsiveness, disease-modifying potential, and long-term organ outcomes.
This is not a semantic issue. It is a regulatory one.
A stem cell–centered model could impact:
- Mechanism-based endpoint selection
- Biomarker qualification strategies
- Trial population stratification
- Surrogate endpoint validation
- Long-term follow-up architecture
In March 2027, we will convene the first international GRADE-based structured consensus to systematically assess this framework.
The goal is alignment — between biology, therapeutic innovation, and regulatory evaluation.
We welcome dialogue with regulatory authorities, HTA bodies, and industry partners interested in biologically coherent development strategies in rare hematologic diseases.
A century after its original description, reassessment may not be disruptive — it may be necessary.”
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 13:44Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
-
Apr 12, 2026, 13:42William Aird: Anemia of Inflammation Not Just a Trade-Off but a Possible Compensation
-
Apr 12, 2026, 13:38Emmanuel J Favaloro: D-dimer testing in VTE diagnostic management studies
-
Apr 12, 2026, 13:26Flora Peyvandi: What Can Be Alternative to Warfarin
-
Apr 12, 2026, 13:21Can We Better Predict Who Is Most Likely to Have Another VTE After a First Event? – RPTH Journal
-
Apr 12, 2026, 13:18Gareth Owens: Advancing Aortic Disease Awareness Through Think Aorta
-
Apr 12, 2026, 13:11Denis Oduor: Apheresis Donation and Blood Component Therapy
-
Apr 12, 2026, 13:04Arsene Mekinian Featured in the Journal of Internal Medicine – Santé Arménie
-
Apr 12, 2026, 13:04Toward Nationwide Hemophilia Care in Armenia by 2030 – WFH